Fate Therapeutics (NASDAQ:FATE) (NASDAQ:FATE) is a clinical-stage biopharmaceutical company dedicated to the development of novel cellular immunotherapies for cancer and immune disorders. The company specializes in the use of induced pluripotent stem cell (iPSC) technology to create off-the-shelf, engineered cell products that harness the body’s natural immune defenses. Fate’s approach aims to deliver standardized, readily available therapeutic cells capable of targeting malignant or dysfunctional cells without the logistical challenges associated with personalized cell therapies.
The company’s pipeline includes both iPSC-derived natural killer (NK) cell and T-cell candidates. Lead programs focus on allogeneic NK cells engineered to express high-affinity, non-cleavable CD16 receptors for enhanced antibody-dependent cytotoxicity, as well as multiplexed CAR-engineered T-cell products designed to recognize and eliminate specific tumor antigens. In addition to monotherapy applications, Fate is advancing combination strategies that pair its cell therapies with established antibody or checkpoint inhibitor regimens to deepen and extend clinical responses.
Founded in 2007 and headquartered in San Diego, California, Fate Therapeutics has built a network of research collaborations and strategic partnerships to augment its platform capabilities. The company works with leading academic institutions and industry partners in North America, Europe and Asia to advance both preclinical research and clinical trial enrollment. This global footprint supports Fate’s objective of rapidly translating laboratory discoveries into scalable, commercial-ready therapies for patients with a range of oncologic and immunologic indications.
Under the leadership of President and Chief Executive Officer Scott Wolchko, Fate Therapeutics employs a multidisciplinary management team with expertise spanning stem cell biology, immuno-oncology, manufacturing and regulatory affairs. The company continues to expand its manufacturing infrastructure to support seamless scale-up of its iPSC-derived products, and it remains focused on delivering clinical data that can validate the safety, efficacy and commercial potential of its off-the-shelf cell therapies.
